Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Beam Therapeutics (BEAM) stocks in Canada

Learn how to easily invest in Beam Therapeutics stocks.

Beam Therapeutics is a biotechnology business based in the US. Beam Therapeutics stocks (BEAM.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $98.05 – a decrease of 7.31% over the previous week. Beam Therapeutics employs 306 staff and has a trailing 12-month revenue of around $781,000.

How to buy shares in Beam Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BEAM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Beam Therapeutics stock price (NASDAQ:BEAM)

Use our graph to track the performance of BEAM stocks over time.

Beam Therapeutics shares at a glance

Information last updated 2022-01-17.
Latest market close$62.86
52-week range$56.34 - $138.52
50-day moving average $80.48
200-day moving average $87.86
Wall St. target price$125.70
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-6.54

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Beam Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Beam Therapeutics price performance over time

Historical closes compared with the close of $62.86 from 2022-01-21

1 week (2022-01-13) -4.94%
1 month (2021-12-20) N/A
3 months (2021-10-22) -32.94%
6 months (2021-07-23) -31.94%
1 year (2021-01-22) -36.83%
2 years (2020-01-20) N/A
3 years (2019-01-20) N/A
5 years (2017-01-20) N/A

Beam Therapeutics financials

Revenue TTM $781,000
Gross profit TTM $-91,956,000
Return on assets TTM -32.22%
Return on equity TTM -76.17%
Profit margin 0%
Book value $12.85
Market capitalisation $4.6 billion

TTM: trailing 12 months

Beam Therapeutics share dividends

We're not expecting Beam Therapeutics to pay a dividend over the next 12 months.

Beam Therapeutics overview

Beam Therapeutics Inc. , a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc. ; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc.

Stocks similar to Beam Therapeutics

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site